Author:
Sarpong Abena Kyeraa,Odoi Hayford,Boakye Yaw Duah,Boamah Vivian Etsiapa,Agyare Christian
Abstract
Abstract
Background
Vulvovaginal candidiasis is a common fungal infection that affects the female lower genital tract. This study determined the major risk factors associated with vulvovaginal infection (VVI) in the Ashanti region of Ghana and also determined the antifungal resistance patterns of Candida albicans isolates to some antifungals.
Methods
Three hundred and fifty (350) high vaginal swab (HVS) samples were collected from women who presented with signs and symptoms of VVI. A structured questionnaire was administered to one hundred and seventy-two (172) of the women. HVS samples were cultured on Sabouraud dextrose agar with 2% chloramphenicol. The polymerase chain reaction was employed to confirm C. albicans. Antifungal susceptibility testing was performed and the susceptibility of C. albicans isolates to fluconazole, clotrimazole, amphotericin B, nystatin, miconazole and 5-flurocytosine were assessed.
Results
Vaginal infection was most prevalent amongst females in their reproductive age (21 to 30 years; 63.0%). The study found a significant association between vaginal infections and some risk factors such as sexual practices (p < 0.001), antibiotic misuse (p < 0.05), poor personal hygiene (p < 0.005) and birth control methods (p < 0.049). Out of the 350 HVS samples collected, 112 yielded yeast cells with 65 (58%) identified as C. albicans. The C. albicans isolates were resistant to 5’ flucytosine (100%), fluconazole (70%), voriconazole (69.2%), miconazole (58.5%) and nystatin (49.2%). C. albicans isolates were more susceptible to amphotericin B (53.8%) and clotrimazole (45.1%), although an appreciable number of isolates showed resistance (46.1% and 52.3%, respectively).
Conclusion
There should be nationwide education on all associated risk factors of VVI. Also, use of the various antifungal agents in vaginal candidiasis should proceed after antifungal susceptibility testing to ensure efficacious use of these agents.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Lusti-Narasimhan M, Pessoa-Silva CL, Temmerman M. Moving forward in tackling antimicrobial resistance: WHO actions. Sex Transm Infect. 2013;89.
2. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399.
3. Dharwad S, Saldanha DRM. Species identification of Candida isolates in various clinical specimens with their antifungal susceptibility patterns. J Clin Diagn Res. 2012;5:1177–81.
4. Kumar S, Kumar A, Roudbary M, Mohammadi R, Černáková L, Rodrigues CF. Overview on the infections related to Rare Candida Species. Pathogens. 2022. 24;11(9).
5. Jabra-Rizk MA, Kong EF, Tsui C et al. Candida albicans pathogenesis: fitting within the host-microbe damage response framework. Infect Immun. 2016;84.